Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy
ConclusionsThis study demonstrates that ribosome-targeting drugs may be effective against diverse CRPC subtypes including AR-null disease, and highlights the potential of contemporary patient-derived models to prioritise treatment strategies for clinical translation.Patient summaryDiverse types of therapy-resistant prostate cancers are sensitive to a new combination of drugs that inhibit protein synthesis pathways in cancer cells.
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Genetics | Legislation | Neurology | Prostate Cancer | Statistics | Study | Urology & Nephrology